Table 1: Baseline Characteristics

	Non-ET (n=9)	ET (n=10)	p value
Age (years)	71.1 ± 13.8	72.3 ± 8.5	0.827
Male, n (%)	9 (100%)	8 (80%)	0.168
Body mass index (kg/m^2)	26.0 ± 2.7	24.2 ± 4.6	0.302
Systolic blood pressure (mmHg)	127.7 ± 22.4	122.4 ± 18.9	0.590
Diastolic blood pressure (mmHg)	76.3 ± 9.7	68.8 ± 8.8	0.096
LVEF (%)	59.4 ± 10.1	58.7 ± 12.0	0.888
E/e' (-)	12.0 ± 3.1	13.7 ± 2.4	0.183
AT-VO$_2$ (ml/min/kg)	10.7 ± 1.7	9.9 ± 1.9	0.372
BUN (mg/dl)	21.1 ± 3.7	21.3 ± 6.0	0.917
Crea (mg/dl)	1.2 ± 0.2	1.2 ± 0.5	0.906
Triglyceride (mg/dl)	116.1 ± 63.3	114.6 ± 41.4	0.952
LDL-C (mg/dl)	93.2 ± 24.7	113.9 ± 31.6	0.129
HDL-C (mg/dl)	50.6 ± 15.9	40.6 ± 7.4	0.113
Risk Factor (%)			
Hypertension	9 (100%)	9 (90%)	1.000
Diabetes Mellitus	2 (22%)	5 (50%)	0.350
Dyslipidemia	9 (100%)	8 (80%)	0.474
Smoking	1 (11%)	1 (10%)	1.000
Therapy Distribution (%)			
Anti-platelet Drugs	7 (78%)	10 (100%)	0.211
ACE-I	2 (22%)	5 (50%)	0.350
ARB	7 (78%)	5 (50%)	0.350
β-blocker	4 (44%)	3 (30%)	0.650
Calcium channel blockers	4 (44%)	7 (70%)	0.370
Diuretic	2 (22%)	3 (30%)	1.000
Statin	7 (78%)	10 (100%)	0.211

Angiotensin converting enzyme inhibitors; ACE-I, Angiotensin II receptor blocker; ARB, Left ventricular ejection fraction; LVEF, ratio of early diastolic flow velocity to early diastolic mitral annular velocity; E/e', Anaerobic metabolic threshold; AT-VO2, High-density and Low-density lipoprotein cholesterol; HDL-C and LDL-C